Drug Approval | July 08, 2022
Lupin’s Somerset manufacturing plant Receives EIR from US FDA
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at Indore plant.
Company is investing more than €100 million in the expansion of the Halle site
Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.
VACUUBRAND has evolved rapidly in recent years, developing new innovative vacuum technology for laboratories, research and engineering
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Subscribe To Our Newsletter & Stay Updated
